Literature DB >> 17025238

Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops.

Mahendra Singh Rathore1, Dipak K Majumdar.   

Abstract

The purpose of this research was to optimize the formulation factors for maximum in vitro permeation of gatifloxacin from aqueous drops through excised goat cornea and to evaluate the permeation characteristics of drug from selected marketed eyedrop formulations. Permeation studies were conducted by putting 1 mL of formulation on the cornea (0.67 cm(2)) fixed between the donor and receptor compartments of an all-glass modified Franz diffusion cell and measuring gatifloxacin concentration in the receptor (containing normal saline under stirring) by spectrophotometry at 291.5 nm, after 120 minutes. Raising the drug concentration of the drops increased the drug permeation but decreased the percent permeation and the in vitro ocular availability. Raising the pH of the formulation from pH 5 to 7.2 increased both the drug permeation and the in vitro ocular availability. Eyedrops containing benzalkonium chloride (BAK; 0.01% wt/vol) and disodium edetate (EDTA; 0.01% wt/vol) showed maximum permeation, followed by Zymar, BAK (0.01% wt/vol), Gatilox, Gatiquin, and Gate (statistically significant P < .05 compared with control). In vitro titration of the formulations with 0.1N NaOH indicated the presence of a buffer in Zymar (pH 6) and Gate (pH 5.8), which may cause irritation and induce lacrimation, resulting in reduced ocular availability in vivo. Thus, formulation with BAK and EDTA, which is unbuffered, has a better likelihood of being absorbed in vivo. The BAK-EDTA formulation significantly (P < .05) increased the permeation of gatifloxacin through paired excised corneas of goat, sheep, and buffalo, compared with the control formulation. The goat cornea showed the greatest increase in permeation, followed by the sheep and buffalo corneas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17025238      PMCID: PMC2750499          DOI: 10.1208/pt070357

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  19 in total

1.  [Norfloxacin: a broad-spectrum quinolone for superficial eye infections].

Authors:  J Grosset
Journal:  Pathol Biol (Paris)       Date:  1990-09

2.  A corneal perfusion device for estimating ocular bioavailability in vitro.

Authors:  J B Richman; D D Tang-Liu
Journal:  J Pharm Sci       Date:  1990-02       Impact factor: 3.534

Review 3.  Treatment of ocular infections with topical antibacterials.

Authors:  J P Leeming
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 4.  Gatifloxacin: a review of its use in the management of bacterial infections.

Authors:  Caroline M Perry; Douglas Ormrod; Miriam Hurst; Susan V Onrust
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Gatifloxacin.

Authors:  C M Perry; J A Barman Balfour; H M Lamb
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

6.  Effect of formulation factors on in vitro permeation of moxifloxacin from aqueous drops through excised goat, sheep, and buffalo corneas.

Authors:  Pravin Kondiba Pawar; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2006-02-10       Impact factor: 3.246

7.  Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis.

Authors:  I Cochereau-Massin; J Bauchet; S Marrakchi-Benjaafar; A Saleh-Mghir; F Faurisson; J M Vallois; E Vallee; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 8.  Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment.

Authors:  Robert Abshire; Paul Cockrum; Julie Crider; Barry Schlech
Journal:  Clin Ther       Date:  2004-02       Impact factor: 3.393

9.  Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.

Authors:  J P Diamond; L White; J P Leeming; H Bing Hoh; D L Easty
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

10.  Ciprofloxacin ophthalmic solution versus rifamycin ophthalmic solution for the treatment of conjunctivitis and blepharitis.

Authors:  J P Adenis; J Colin; P Verin; P Saint-Blancat; F Malet
Journal:  Eur J Ophthalmol       Date:  1995 Apr-Jun       Impact factor: 1.922

View more
  17 in total

1.  Effect of pH and formulation variables on in vitro transcorneal permeability of flurbiprofen: a technical note.

Authors:  Sajeev Chandran; Archna Roy; Ranendra N Saha
Journal:  AAPS PharmSciTech       Date:  2008-09-16       Impact factor: 3.246

2.  Evaluation of gatifloxacin pluronic micelles and development of its formulation for ocular delivery.

Authors:  Jovita Kanoujia; Priya Singh Kushwaha; Shubhini A Saraf
Journal:  Drug Deliv Transl Res       Date:  2014-08       Impact factor: 4.617

3.  Systematic review and Meta-analysis comparing modified cross-linking and standard cross-linking for progressive keratoconus.

Authors:  Yang Liu; Yi Liu; Ying-Nan Zhang; Ai-Peng Li; Jing Zhang; Qing-Feng Liang; Ying Jie; Zhi-Qiang Pan
Journal:  Int J Ophthalmol       Date:  2017-09-18       Impact factor: 1.779

Review 4.  Current perspectives on corneal collagen crosslinking (CXL).

Authors:  Sandeepani K Subasinghe; Kelechi C Ogbuehi; George J Dias
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-04-06       Impact factor: 3.117

5.  Ex vivo rabbit cornea diffusion studies with a soluble insert of moxifloxacin.

Authors:  María Sebastián-Morelló; María Aracely Calatayud-Pascual; Vicent Rodilla; Cristina Balaguer-Fernández; Alicia López-Castellano
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

6.  BAC-EDTA transepithelial riboflavin-UVA crosslinking has greater biomechanical stiffening effect than standard epithelium-off in rabbit corneas.

Authors:  Andre A M Torricelli; Matthew R Ford; Vivek Singh; Marcony R Santhiago; William J Dupps; Steven E Wilson
Journal:  Exp Eye Res       Date:  2014-06-12       Impact factor: 3.467

7.  Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.

Authors:  Guy E Thwaites; Sujata M Bhavnani; Tran Thi Hong Chau; Jeffrey P Hammel; M Estée Török; Scott A Van Wart; Pham Phuong Mai; Daniel K Reynolds; Maxine Caws; Nguyen Thi Dung; Tran Tinh Hien; Robert Kulawy; Jeremy Farrar; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

8.  Aliphatic β-nitroalcohols for therapeutic corneoscleral cross-linking: corneal permeability considerations.

Authors:  Quan Wen; Stephen L Trokel; MiJung Kim; David C Paik
Journal:  Cornea       Date:  2013-02       Impact factor: 2.651

9.  [Morphological alterations induced by preservatives in eye drops].

Authors:  K K Huber-van der Velden; H Thieme; M Eichhorn
Journal:  Ophthalmologe       Date:  2012-11       Impact factor: 1.059

10.  RES-loaded pegylated CS NPs: for efficient ocular delivery.

Authors:  Saravanakumar Pandian; Vinoth Jeevanesan; Chandrasekar Ponnusamy; Subramanian Natesan
Journal:  IET Nanobiotechnol       Date:  2017-02       Impact factor: 1.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.